Effects of extended-release tramadol on pain-related sleep parameters in patients with osteoarthritis

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 11, 2008, Pages 1817-1827

  Florete, Orlando G ^a   Xiang, Jim ^b   Vorsanger, Gary J ^b  

^a BAPTIST MEDICAL CENTER   (United States)

^b Ortho McNeil Pharmaceutical Incorporated   (United States)

Author keywords

Chronic pain; Osteoarthritis; Sleep problems; Tramadol

Indexed keywords

ANALGESIC AGENT; PLACEBO; TRAMADOL;

ANALGESIA; ANALGESIC ACTIVITY; ARTHRALGIA; ARTICLE; CHRONIC PAIN; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DISEASE CLASSIFICATION; DISEASE DURATION; DIZZINESS; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEADACHE; HUMAN; KNEE PAIN; MORNING DOSAGE; NAUSEA; OSTEOARTHRITIS; POST HOC ANALYSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; SLEEP DEPRIVATION; SLEEP DISORDER; SLEEP PATTERN; VISUAL ANALOG SCALE;

ADULT; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS; PAIN; PAIN MEASUREMENT; SLEEP DISORDERS; TRAMADOL;

EID: 49649108544     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.11.1817     Document Type: Article

References (34)

1. Jordan JM, Bernard SL, Callahan LF, et al. Self reported arthritis-related disruptions in sleep and daily life and the use of medical. complementary, and self-care strategies for arthritis: the National Survey of Self-care and Aging. Arch Fam Med 2000;9:143-9
2. Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected muscusloskeletal disorders in the United States. Arthritis Rheum 1998;41:778-99
3. National Institutes of Health, National Institute of Arthritis and Musculoskeletal Diseases. Osteoarthritis. Handout on Health. NIH Publication No. 02-4617. US Department of Health and Human Services; 2002
4. Ricci JA, Stewart WF, Chee E, et al. Pain exacerbation as a major source of lost productive time in US workers with arthritis. Arthritis Rheum 2005;53:673-81
5. Caldwell JR, Hale ME, Boyd RE, et al. Treatment of osteoarthritis pain with controlled release oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteroidal and-inflammatory drugs: a double blind, randomized, multicenter, placebo-controlled trial. J Rheumatol 1999;26:862-9
6. Salaffi F, Carotti M, Stancati A, Grassi W. Health-related quality of life in older adults with symptomatic hip and knee osteoarthritis: a comparison with matched healthy controls. Aging Clin Exp Res 2005;17:255-63
7. Dominick KL, Ahern FM, Gold CH, Heller DA. Health-related quality of life among older adults with arthritis. Health Qual Life Outcomes 2004;2:5
8. Menefee LA, Frank ED, Doghramji K, et al. Self-reported sleep quality and quality of life for individuals with chronic pain conditions. Clin J Pain 2000;16:290-7
9. Deardorff W. Breaking the cycle of chronic pain and insomnia. Available from: http://www.spine-health.com/topics/conserv/insomnia/insomnial.html [Last accessed 21 February 2007]
10. Wilcox S, Brenes GA, Levine D, et al. Factors related to sleep disturbance in older adults experiencing knee pain or knee pain with radiographic evidence of knee osteoarthritis. J Am Geriatr Soc 2000;48:1241-51
11. Morin CM, Gibson D, Wade J. Self-reported sleep and mood disturbance in chronic pain patients. Clin J Pain 1998;14:311-4
12. Nicassio PM, Wallston KA. Longitudinal relationships among pain, sleep problems, and depression in rheumatoid arthritis. J Abnorm Psychol 1992;101:514-20
13. Adler L, McDonald C, O'Brien C, Wilson M. A comparison of once-daily tramadol with normal release tramadol in die treatment of pain in osteoarthritis. J Rheumatol 2002;29:2196-9
14. Caldwell JR, Rapoport RJ, Davis JC, et al. Efficacy and safety of a once-daily morphine formulation in chronic, moderate-to-severe osteoarthritis pain: results from a randomized, placebo-controlled, double-blind trial and an open-label extension trial. J Pain Symptom Manage 2002;23:278-91
15. Kivitz A, Ma C, Ahdieh H, Galer BS. A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, Phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthtitis of the hip or knee. Clin Ther 2006;28:352-64
16. Kosinski M, Janagap CC, Gajria K, Schein J. Psychometric testing and validation of the Chronic Pain Sleep Inventory. Clin Ther 2007;29(Suppl 1):2562-77
17. Gana TJ, Pascual MLG, Fleming RRB, et al. Extended-release tramadol in the treatment of osteoarthritis: a multicenter, randomized, double-blind, placebo-controlled clinical trial. Curr Med Res Opin 2006;22:1391-401
18. Kosinski M, Janagap C, Gajria K, et al. Pain relief and pain-related sleep disturbance with extended-release tramadol in patients with osteoarthritis. Curr Med Res Opin 2007;23:1615-26
19. ULTRAM® ER (tramadol HCl) Extended-Release Tablets [package insert]. Raritan, NJ: PriCara™, a unit of Ortho-McNeil, Inc.; 2006
20. Xiang J, Janagap C, Jordan D, Vorsanger G. Effects of extended-release tramadol on pain-related sleep parameters in osteoarthritis. J Pain 2007;8:S37
21. American College of Rheumatology. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum 2000;43:1905-15
22. Lautenbacher S, Kundermann B, Krieg JC. Sleep deprivation and pain perception. Sleep Med Rev 2005
23. Menefee LA, Cohen MJ, Anderson WR, et al. Sleep disturbance and nonmalignant chronic pain: a comprehensive review of the literature. Pain Med 2000;1:156-72
24. Casarett D, Karlawish J, Sankar P, et al. Designing pain research from the patient's perspective: what trial end points are important to patients with chronic pain? Pain Med 2001;2:309-16
25. Dionne RA, Bartoshuk L, Mogil J, Witter J. Individual responder analyses for pain: does one pain scale fit all? Trends Pharmacol Sci 2005;26:125-30
26. Miaskowski C, Dodd M, West C, et al. The use of a responder analysis to identify differences in patient outcomes following a self-care intervention to improve cancer pain management. Pain 2007;129:55-63
27. Jensen MP, Friedman M, Bonzo D, Richards P. The validity of the neuropathic pain scale for assessing diabetic neuropathic pain in a clinical trial. Clin J Pain 2006;22:97-103
28. Farrar JT, Portenoy RK, Berlin JA, et al. Defining the clinically important difference in pain outcome measures. Pain 2000;88:287-94
29. Barkin RL. Extended-release tramadol (ULTRAM®ER): a pharmacotherapeutic. pharmacokinetic, and pharmacodynamic focus on effectiveness and safety in patients with chronic/persistent pain. Am J Ther 2008;15:157-66
30. Klotz U. Tramadol - the impact of its pharmacokinetic and pharmacodynamic properties on the clinical management of pain. Arzneimittelforschung 2003;53:681-7
31. ULTRAM® (tramadol hydrochloride tablets) [package insert]. Raritan, NJ: Ortho-McNeil Pharmaceutical, Inc.; 2004
32. Vizcaychipi MP, Walker S, Palazzo M. Serotonin syndrome triggered by tramadol. Br J Anaesth 2007;99:919
33. Mahlberg R, Kunz D, Sasse J, Kirchheiner J. Serotonin syndrome with tramadol and citalopram. Am J Psychiatry 2004;161:1129
34. Kitson R, Carr B. Tramadol and severe serotonin syndrome. Anaesthesia 2005;60:934-5